PURPOSE: This study set out to examine the survival and progression-free outcomes in aggressive lymphoma patients receiving (R)CEOP therapy due to contraindications for anthracycline therapy. Toxicities that developed were also evaluated and reported. ----- PATIENTS & METHODS: Hospital records were searched for patients who received (R)CEOP in >50% of chemotherapy cycles. A total of 44 patients were included from KBC Zagreb, with 33 B cell lymphoma and 11 T cell lymphoma patients. Data was analyzed to evaluate survival, risk factors, and toxicities. ----- RESULTS: Patients were followed up a median of 30.3 months. The 5 year overall survival rate was approximately 48% and event-free survival 40%. It was found that elevated LDH at diagnosis and age >70 years are poor prognostic factors, having a statistically significant correlation to poorer overall survival. All other risk and prognostic factors were not found to have a statistically significant impact on survival. The most commonly encountered toxicities were cytopenias and infections (34% and 34%). ----- CONCLUSION: (R)CEOP therapy is generally well-tolerated in patients with co-morbidities that preclude traditional anthracycline therapy. Elevated LDH and advanced age are poor prognostic factors for survival. This study found no statistically significant difference according to cell of origin in DLBCL patients and survival outcomes.